By Kayla J. Spivey, Thermo Fisher Scientific
With the demand created by mRNA vaccines and compounded by the emerging cell and gene therapy market, the need for large-scale production of GMP-grade materials for biological products has never been greater.
Finding a way to increase manufacturing capacity while maintaining high-quality standards poses a unique challenge. The demand for reproducible, high-quality, and customizable bioprocessing material is forecasting its continued growth through 2025.
Culture medium and fermentation protocols are pivotal in maintaining a high-quality optimal percent yield while minimizing contaminants that will need to be removed during purification and downstream process steps. Here we will discuss the scalable process workflow solutions available from initial R&D investment to clinical testing, and commercialization.